NeOnc’s 2Q26 update meaningfully strengthens the clinical setup, with NEO100 meeting its Phase 2a primary endpoint and generating a notable overall survival signal of 26.09 months versus the 6–9 months management cites for current salvage therapy. The favorable safety profile, at-home administration, and lack of major toxicities support the potential for NEO100 to shift recurrent high-grade glioma toward a more chronic treatment paradigm, although the single-arm dataset still requires confirmation in a randomized study. The next major catalyst is FDA alignment through a planned Type B meeting, which should provide clarity on a registrational pathway for NEO100, while NEO212 continues advancing toward Phase 2 following recent CMC feedback. With development activity expanding, access to capital remains an important consideration given the $2.0M cash balance and $11.8M of operating cash use through the first six months of 2026.
